This week's biggest % winners & losers : Dec. 13 - 17, 2021 (wk 50)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: ARNA (91.24 +82.7%), TRHC (15.59 +47.08%), NVAX (213.88 +28.41%), BHVN (122.89 +23.22%), PBYI (3.51 +23.16%), CERN (90.51 +21.7%), OPK (4.64 +19.98%), QDEL (160.49 +19.71%), ICPT (17.12 +19.22%), EGRX (54.38 +18.68%), ANAB (35.23 +17.43%), IRTC (105.24 +16.84%), KURA (14.21 +16.28%), FATE (56.81 +15.55%), ACAD (25.7 +15.45%), EPZM (3.17 +14.26%), VAPO (23.5 +14.19%), BLUE (10.23 +14.17%), ALLK (82.93 +13.91%)
• Information Technology: CCMP (187.31 +25.77%)

This week's top % losers

• Healthcare: QURE (20.62 -27.01%), MESO (4.72 -23.38%), BEAT (2.95 -22.7%), ENDP (3.7 -20.88%)
• Industrials: RUN (33.74 -20.24%), REVG (13.43 -18.21%)
• Consumer Discretionary: CPS (19.07 -26.57%), LOVE (64.34 -20.87%), CVNA (220.76 -18.48%), MOGU (0.43 -18.1%), BKE (41.46 -17.93%), TAL (4.19 -17.13%)
• Information Technology: HOLI (12.14 -18.3%)
• Financials: FANH (8.58 -19.96%), LC (23.55 -19.49%)
• Energy: SWN (4.5 -18.18%), NINE (1.06 -17.19%), CPG (4.4 -16.92%)

Arena Pharma (ARNA) to be acquired by Pfizer (PFE) for $100/share or $6.7B

• Pfizer has agreed to buy U.S. biotech company Arena Pharmaceuticals in a deal valued at about $6.7 billion.
• The U.S. pharma giant said the acquisition would expand its cancer and inflammatory disease drug pipeline.

** ARNA **

 

 

 

Analysts: Pfizer to 'capitalize' on experimental colitis treatment in Arena deal 

 "We view PFE as a logical partner for ARNA as the latter continues to progress its gastroenterology, dermatology, and cardiology focused platform, which should benefit from the executional expertise of a large pharmaceutical company," SVB Leerink analyst Joseph Schwartz told analysts in a research note. "PFE's commercial framework can capitalize on etrasimod's best-in-class potential," wrote RBC Capital Markets' Kennen MacKay. The one thing that surprised Wall Street was Pfizer's decision to execute a deal before the upcoming readout of Phase 3 clinical trial data for Arena's etrasimod, an experimental ulcerative colitis treatment. That data is expected early next year. Pfizer's stock has gained 43.4% so far this year, while Arena's shares are down 35.0%. 

This week's biggest % winners & losers: Nov 9 - 13, 20 (wk 46)

This week's biggest % gainers/losers The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: FPRX (21.17 +323.4%), BKD (4.1 +48.37%)
• Industrials: TISI (8.50 +52.06%), SPR (30.21 +39.13%), CPA (70.98 +38.74%)
• Consumer Discretionary: TOUR (1.57 +44.91%), LE (22.59 +42.79%)
• Information Technology: EBIX (27.73 +42.77%)
• Energy: NR (1.19 +43.46%)
• Consumer Staples: CHEF (19.47 +38.53%)

This week's top % losers

• Healthcare: QDEL (199.86 -29.49%), ACB (7.06 -27.87%), BIIB (248.28 -24.51%), ARNA (66.58 -23.15%), TLRY (7.57 -21.44%), FLDM (5.95 -21.36%)
• Materials: HMY (4.81 -17.58%), GFI (10.65 -17.35%)
• Industrials: GFF (19.66 -16.71%)
• Consumer Discretionary: NLS (20.76 -25.32%), OSTK (54.67 -18.8%), STMP (185.03 -17.5%), HOME (14.1 -15.37%)
• Information Technology: RAMP (60.28 -20.72%), TWOU (32.68 -17.37%), CCMP (135.8 -15.18%)
• Energy: HPR (3.6 -34.19%), GLOP (2.16 -30.64%)
• Consumer Staples: NBEV (2.65 -18.36%)

Arena Pharma (ARNA) reported earnings on Mon 9 Nov 20 (a/h)

  ** charts after earnings **

 

 

 

 

 

 

 

 

Arena Pharm beats by $0.17, misses on revs, provides clinical program update

• Reports Q3 (Sep) loss of $(1.69) per share, $0.17 better than the S&P Capital IQ Consensus of ($1.86); revenues fell 98.5% year/year to $0.02 mln vs the $1.43 mln S&P Capital IQConsensus.

Program Updates:

• Etrasimod atopic dermatitis (AD) ADVISE Phase 2b trial delivered topline results; moving forward into a Phase 3 registrational program
• Etrasimod ELEVATE UC 52 Phase 3 trial in ulcerative colitis (UC) ongoing and on track to complete enrollment by year-end 2020, with the 52-week treatment period ending by year-end2021 and data expected shortly thereafter; ELEVATE UC 12 Phase 3 trial was initiated, continues to make strong progress with data expected in the same timeframe as UC 52; we continue to monitor the impact of the COVID-19 resurgence on study enrollment for both UC52 and UC 12
• Etrasimod GLADIATOR UC Phase 2 planning; initiation expected in Q1 2021 dependent onCOVID-19 impact
• Etrasimod CULTIVATE Phase 2/3 trial in Crohn's disease (CD) ongoing; confirming topline dose-ranging data in 2021; continue to suspend overall program guidance based on COVID-19impact
• Etrasimod eosinophilic esophagitis (EoE) Phase 2b VOYAGE trial with initiation expected in 2020but dependent on COVID-19 impact
• Etrasimod alopecia areata (AA) Phase 2 initiated; topline data expected H2 2021
• Olorinab CAPTIVATE Phase 2b trial in abdominal pain associated with irritable bowel syndrome(IBS-C, IBS-D) enrollment completed; topline data expected Q1 2021
• APD418 in acute heart failure (AHF) with Fast Track designation; completed the first-in-human Phase 1 trial; APD418 was generally well tolerated; Phase 2 planning ongoing

Arena Pharm announces top-line results from Phase 2b ADVISE trial evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis; primary endpoint not met

• Arena Pharmaceuticals today announced top-line results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P)receptor modulator, for the treatment of moderate-to-severe atopic dermatitis (AD).
• In the ADVISE trial, the participants were representative of a moderate patient population(82.9% baseline vIGA 3). In the primary analysis, nearly one-third of participants in the 2 mgetrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA) -- the FDA endpoint for Phase 3 registration. Importantly, the vIGA improvement was statistically significant vs. placebo at 12 weeks. Across the Eczema Area and Severity Index (EASI), EASI-75 and peak change in pruritis, etrasimod 2 mg demonstrated early and statistically significant effect at week 4.
• Etrasimod did not meet the Ph 2b primary endpoint of EASI change from baseline at week 12 as compared to placebo.
• Overall, the 12-week study showed no plateau of effect, and the safety profile was consistent with previous trials of etrasimod including low first dose heart rate effect with no titration, and no serious adverse events across the groups.
• Between weeks 4-8, the trial was impacted by unwarranted dose interruption (not related to drug safety) in 19% of the etrasimod 2 mg group. Adjusting for this dose interruption --a post-hoc Completer Analysis with participants receiving full therapeutic exposure -- etrasimod2 mg showed statistically significant effect on the EASI score compared to placebo (weeks 4and 12), EASI-75 at week 4, vIGA at week 12, and pruritis through week 8.

Earnings this week : Nov 9 - 13, 20 (wk 46)

 Monday (Oct 9)

• Morning: ALE BHVN BKI BCOR BIP CNNE CGC CARS EBIX GOGO HL HWM ICPT MCD BTU PLUG RDNT RETA TGNA
• Afternoon: AL AMBC ARNA BYND ELY SCOR DHT DIOD STAY GSKY HAIN IHRT INO IPAR IFF RAMP MBI MWA MYGN NHI NBIX NGL NKLA NCLH NVAX OSH OXY OR CNXN RPAY RNG SCSC SWAV SPG SPT TLND TCO REAL TLRY WES WPM ZIXI ZGNX ZI

Tuesday (Oct 10)

• Morning: AAP AER BNTX CAE IMOS CRSR CYBR DHI ERJ NOVT ROK TCP
• Afternoon: TXG ONEM ADPT AKCA ALC DOX ASH BRKS COHR CVET DDOG FICO FOXF GO HCAT IQ KRNT LYFT MODN PLMR PRSP PRPL RXT RKT SANM SILK TME

Wednesday (Oct 11)

• Morning: ADNT APD APG GIB DOYU HUYA LMND
• Afternoon: ATO CCMP ENS GTBIF HI MFC RVLV REYN SPTN TTEK VRM

Thursday (Oct 12)

• Morning: BAM EPC DAVA ENR GDRX HIMX INMD MTOR NICE NVMI PDD SBH SDGR SSRM SSYS TGP TNK TDG TUFN WIX
• Afternoon: AQN AMWL AMAT CSCO DLB FTCH GLOB NARI JAMF PLTR U DIS

Friday (Oct 13) 

• Morning: DKNG MANU SPB VIPS

Arena Pharma (ARNA) : positive phase 2 results from the OASIS trial for etrasimod in patients with ulcerative colitis

 

** the following day **

Arena Pharma (halted) reports positive phase 2 results from the OASIS trial for etrasimod in patients with ulcerative colitis 

• Relative to placebo, there was a statistically significant (p = 0.009) 0.99 point improvement in a 3-component (stool frequency, rectal bleeding and findings on endoscopy) Mayo Clinic Score (ranging from 0 to 9) with etrasimod 2 mg at week 12. In the 1 mg group, there was a 0.43 point improvement in 3-component Mayo Clinic Score at week 12 relative to placebo, which was not statistically significant (p = 0.146). Significantly more patients in the etrasimod 2 mg group achieved endoscopic improvement compared with placebo (41.8% vs. 17.8%, p = 0.003).
• The proportion of patients achieving clinical remission, defined by the 3-component Mayo Clinic Score, was 33.0% in the etrasimod 2 mg group compared to 8.1% for the placebo group. Remission as defined by the 4-component Total Mayo Clinic Score was 24.5% and 6.0% for etrasimod 2 mg and placebo, respectively.

** charts before **

 

** chart 2 months later **

This week's biggest % winners & losers : Jan 2 - 5, 18 (wk 1)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: CCXI (8.45 +42.02%), CHRS (12.35 +40.34%), TRVN (2.02 +26.25%), MNTA (17.55 +25.81%), ITCI (17.47 +20.65%), GNMK (5.03 +20.62%), ARNA (40.84 +20.22%), NTLA (22.71 +18.16%)
• Materials: UAN (4.04 +23.17%), SID (2.9 +18.37%), CMC (24.9 +16.79%)
• Consumer Discretionary: JMEI (3.62 +23.97%), FCAU (21.77 +22.03%)
• Information Technology: RENN (12.99 +25.02%), ANGI (12.76 +21.99%), SQ (41.14 +18.66%)
• Financials: OMF (34.53 +32.86%)
• Energy: PKD (1.25 +25%), EC (17.15 +17.22%)

This week's top 20 % losers

• Healthcare: RGNX (27.85 -16.24%), PEN (85.15 -9.51%)
• Industrials: BLDP (3.97 -9.98%)
• Consumer Discretionary: FRAN (5.95 -18.6%), CATO (13.11 -17.65%), BKS (5.6 -16.42%), LB (50.36 -16.37%), SPWH (5.77 -12.71%), ASNA (2.06 -12.34%), FINL (13.06 -10.12%), EXPR (9.15 -9.85%), BKE (21.65 -8.84%), BPI (7.6 -8.43%), FRED (3.71 -8.4%)
• Information Technology: SFUN (4.81 -13.8%), GTT (42.75 -8.95%)
• Consumer Staples: UNFI (44.88 -8.91%)
• Telecommunication Services: CBB (18.2 -12.71%)

Long trade : ARNA +20% (1/18)

a.  Dec. 21:   $31, vol. 554K;   Dec. 27:  $34.12   →    +10%
b.  Jan. 2:  $36, vol. 839K;   Jan. 4:  $41  →    +13%

  

*****

This week's biggest % winners & losers: July 10 - 14, 17 (wk 28)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: ARNA (24.28 +26.13%), TRVN (2.78 +23.01%), FOLD (12.84 +22.99%), HRTX (15.45 +20.23%)
• Materials: NAK (1.49 +18.25%)
• Industrials: HTZ (15.22 +30.31%), GNK (10.91 +20.42%)
• Consumer Discretionary: MYCC (17.1 +30.53%), LILAK (26.03 +19.62%), LILA(26.11 +17.09%)
• Information Technology: AAOI (84.2 +25.11%), BZUN (29.5 +17.44%), SPWR(10.12, +15.79%),  KEM (16.07 +15.78%)
• Energy: HK (6.78 +61.43%), PES (2.5 +35.14%), NVGS (10.75 +25.73%), FMSA(3.74 +16.15%), REN (32.7 +16%)
• Utilities: NRG (23.24 +43.1%)

This week's top 20 % losers

• Healthcare: RVNC (23.45 -14.1%), TBPH (37.11 -12.81%), GEN (1.5 -9.64%), COLL (12.23 -8.94%), LMAT (29.14 -8.91%)
• Industrials: MSM (73.66 -17.27%)
• Consumer Discretionary: ANF (8.89 -26.89%), BNED (7.76 -24.14%), HOV (2.45 -14.93%), BGFV (11.5 -9.09%), FRGI (18.25 -7.83%)
• Information Technology: ATEN (6.92 -14.46%), CYBR (42.68 -13.43%), HLIT (4.68 -12.62%), COMM (35.13 -7.92%), ACIA (39 -7.74%)
• Consumer Staples: SFS (7.75 -8.82%)
• Telecommunication Services: CNSL (17.96 -13.28%), CBB (17.35 -10.34%)

Arena Pharmaceuticals (ARNA): Ralinepag positive in phase II PAH study

• Arena Pharmaceuticals (ARNA) reported its pulmonary arterial hypertension (PAH) treatment ralinepag demonstrated a significantly positive results in a phase 2 clinical trial involving 61 patients.
• It is an experimental drug to treat a rare form of lung disease.
• The biotech will now move to a Phase 3 clinical program. 

  

Arena Pharmaceuticals (ARNA) said that an experimental drug that targets a rare but deadly lung disease met its primary goal in a Phase II study.

Arena said that ralinepag, its treatment for pulmonary arterial hypertension, improved pulmonary vascular resistance (PVR) compared to a placebo in a 61-person study. 

Arena Pharmaceuticals (ARNA) before FDA decision on Wed 6/27/12

Arena Pharmaceuticals (ARNA) shares tumbled Friday, and activity in options shot higher, ahead of a key ruling from the U.S. Food and Drug Administration on the company's weight-loss drug.

  

Options watchers said stock holders were moving into options as a way to play the FDA ruling while limiting risk. A decision is expected Wednesday on the company's weight-loss drug candidate lorcaserin. If given the go-ahead, lorcaserin would be the first prescription diet drug to receive U.S. approval in more than a decade.

A lot of the downward pressure on the stock appeared to come from investors taking profits and moving into options ahead of the decision, according to William Lefkowitz, options strategist at vFinance.

"It looks like investors are taking profit, but then rolling some of that profit into 'call' options," said Mr. Lefkowitz. "They still get to participate if the news is really good next week, but they get to limit their losses to what they put into the options."

Call options grant the right to buy stock at a set price by a designated date. When an investor buys a call option, the risk is limited to the cost of that option. Even if the shares fall sharply, the trader's maximum loss remains the price paid for the option.

Arena shares dropped $1.80, or 15%, to $9.88 Friday after the shares had more than quintupled in value leading up to the decision. Just three months ago, the shares traded at $2.

Activity in call options was strong across the board, with options expiring in July busy at the $10 through $15 strike prices. Meanwhile, weekly options expiring next Friday were also active, with $12 and $15 call options seeing the most action.

Yet not all option buyers were as optimistic ahead of the advisory-panel decision.

One trader bought more than 9,300 July $8 put options, which grant the right to sell shares at that price, for $1.61 a piece. That means the stock must drop at least 36% over the next four weeks for the bet to break even.

Arena has been unprofitable every quarter since March 2001, according to FactSet data.

Options activity in the San Diego pharmaceutical company soared to more than four times the daily average Friday. The high price of option contracts suggests traders are pricing in a nearly 50% swing one way or the other in the wake of the FDA decision.

*** 2 days after the FDA approval ***
all gains (400%) happened in the few months leading to the decision